Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.

Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.